KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Retained Earnings (2016 - 2025)

Historic Retained Earnings for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to -$1.3 billion.

  • NovoCure's Retained Earnings fell 1632.5% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 1632.5%. This contributed to the annual value of -$1.2 billion for FY2024, which is 1711.08% down from last year.
  • As of Q3 2025, NovoCure's Retained Earnings stood at -$1.3 billion, which was down 1632.5% from -$1.2 billion recorded in Q2 2025.
  • NovoCure's Retained Earnings' 5-year high stood at -$631.7 million during Q1 2021, with a 5-year trough of -$1.3 billion in Q3 2025.
  • In the last 5 years, NovoCure's Retained Earnings had a median value of -$888.9 million in 2023 and averaged -$905.2 million.
  • Per our database at Business Quant, NovoCure's Retained Earnings skyrocketed by 235.42% in 2021 and then crashed by 2661.61% in 2023.
  • NovoCure's Retained Earnings (Quarter) stood at -$685.9 million in 2021, then dropped by 13.49% to -$778.5 million in 2022, then decreased by 26.6% to -$985.5 million in 2023, then fell by 17.11% to -$1.2 billion in 2024, then dropped by 9.68% to -$1.3 billion in 2025.
  • Its Retained Earnings stands at -$1.3 billion for Q3 2025, versus -$1.2 billion for Q2 2025 and -$1.2 billion for Q1 2025.